Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing abacavir (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing abacavir and lamivudine and zidovudine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Abacavir sulfate 300mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Abacavir sulfate 20mg/mL solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Abacavir sulfate + lamivudine + zidovudine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Product containing precisely abacavir 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Abacavir (as abacavir sulfate) 20 mg/mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Abacavir sulfate (substance) |
Is a |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Abacavir sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Product containing abacavir and lamivudine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Product containing abacavir and lamivudine and zidovudine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
|
Allergy to abacavir |
Causative agent (attribute) |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Abacavir-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing abacavir and lamivudine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing abacavir and dolutegravir and lamivudine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing abacavir and dolutegravir and lamivudine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely abacavir 300 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely abacavir 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir sulfate (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
|
Product containing abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 300 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely abacavir 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir (as abacavir sulfate) 20 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Abacavir only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Abacavir and lamivudine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir and dolutegravir and lamivudine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing only abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing only abacavir (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing only abacavir and lamivudine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir and dolutegravir and lamivudine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing only abacavir and lamivudine and zidovudine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir (as abacavir sulfate) 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Abacavir (as abacavir sulfate) 600 mg and lamivudine 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir (as abacavir sulfate) 60 mg dispersible oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely abacavir (as abacavir sulfate) 120 milligram and lamivudine 60 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Hypersensitivity to abacavir (finding) |
Causative agent (attribute) |
True |
Abacavir (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely abacavir (as abacavir sulfate) 600 milligram and dolutegravir (as dolutegravir sodium) 50 milligram and lamivudine 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |
Abacavir hydrochloride (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
|
Product containing precisely abacavir (as abacavir hydrochloride) 600 milligram and lamivudine 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Abacavir (substance) |
Inferred relationship |
Some |
2 |